Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $161.49 +1.00%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $1.84, $0.24 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.32 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.2-4.5 billion, versus the consensus of $5.61 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
